In addition, Cubist will be consulted concerning any matters that could cause a delay in completion of the Facility.
In addition, Cubist may not be consulted concerning any matters that could cause a delay in completion of the Facility.
Cubist may also terminate this Agreement in the event that the FDA refuses to approve the Product.
Cubist may not terminate terminate this Agreement even in the event that the FDA refuses to approve the Product.
(b) Cubist shall not be required to pay DSM for any Product which has been property rejected in accordance with clause 3.11 sub (a).
(b) Cubist may be required to pay DSM for any Product which has been properly rejected in accordance with clause 3.11 sub (a).
Cubist shall at all times upon reasonable notice and during normal business hours have the right to inspect the Facility to ascertain compliance with GMPs.
Cubist may not be, at all times and upon reasonable notice and normal business hours, denied an inspection of the Facility to ascertain compliance with GMPs.